CARsgen Launches First-in-Class Anti-Claudin18
CARsgen Launches First-in-Class Anti-Claudin18.Two CAR-T Clinical Trial
SHANGHAI , Aug. Ten, two thousand seventeen /PRNewswire/ — CARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced its first-in – class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has entered into phase-I clinical trial and starts patients recruitment at Changhai Hospital of Shanghai , a renowned hospital of global reputation for expertise on gastroesophageal and related cancer. …